Intel Corporation (INTC.US) has had its fine reduced by 1.4 billion euros by the European Court of Justice: the once record-breaking penalty has been reduced.
Intel received an additional reduction of nearly 140 million euros (163 million dollars) in the record-breaking EU antitrust fine.
Intel Corporation (INTC.US) has successfully reduced the remaining amount of an EU antitrust fine by nearly 1.4 billion euros (approximately 1.63 billion US dollars). The fine's initial amount had previously set a record.
Judges at the European Union General Court in Luxembourg upheld the EU Commission's 2023 decision that Intel Corporation abused its market power in the chip market. However, the judges ruled that the fine should be further reduced from the regulator's previous 3.7636 billion euro penalty, which had already been significantly reduced following a previous court ruling.
In its ruling on April 30, the court stated that the reduced fine amount of around 2.371 billion euros, "more accurately reflects the seriousness and duration of the relevant infringement." The European Commission, as the EU antitrust enforcement agency, stated that it would "carefully study the judgment and assess the possibility of further steps."
In 2023, after an EU court overturned a previous 1.06 billion euro fine against the chipmaker, the antitrust regulator imposed a lower fine on Intel Corporation.
At that time, the EU Commission fined Intel Corporation for "engaging in a series of anticompetitive practices aimed at excluding competitors from relevant markets, in violation of EU antitrust rules," and for "abusing its dominant market position in the market for computer chips known as x86 central processors."
Related Articles

C.Q. Pharmaceutical Holding (000950.SZ), a shareholder of Drug Friend Pharmaceutical, signed a licensing agreement with Pfizer.

GUOFUHEE (02582) plans to repurchase H shares.

HEALTHYWAY INC (02587) spent 1.2154 million Hong Kong dollars to repurchase 258,000 shares on December 10th.
C.Q. Pharmaceutical Holding (000950.SZ), a shareholder of Drug Friend Pharmaceutical, signed a licensing agreement with Pfizer.

GUOFUHEE (02582) plans to repurchase H shares.

HEALTHYWAY INC (02587) spent 1.2154 million Hong Kong dollars to repurchase 258,000 shares on December 10th.

RECOMMEND

McDonald’s to Evaluate Franchisee Pricing for Customer Value Under Revised Standards
10/12/2025

Baidu’s AI Ace Kunlunxin Prepares For Hong Kong IPO, Domestic Computing Power Faces Crucial Test
08/12/2025

Institutions Say Short-Term Volatility Does Not Alter Upward Trend Of Hong Kong Stocks, Hang Seng Index Still Expected To Challenge 30,000 Points Next Year
08/12/2025


